Dyax’s BLA For Acute Hereditary Angioedema Goes Before FDA Advisory Panel In February
This article was originally published in The Pink Sheet Daily
Executive Summary
DX-88 could be one step closer to becoming the first treatment approved for acute attacks of HAE; Pulmonary-Allergy Drugs Advisory Committee review is Feb. 4.